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Highlights 
 
 We reviewed the literature of functional brain changes in preclinical dementia. 
 Functional brain changes occur very early in individuals at risk of AD. 
 There is less consensus on the directionality of functional changes. 
 Spatial extent of changes in preclinical dementia overlaps with brain regions in AD. 
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ABSTRACT 
It is well established that the neurodegenerative process of Alzheimer's disease (AD) begins many years 
before symptom onset. This preclinical phase provides a crucial time-window for therapeutic intervention, 
though this requires biomarkers that could evaluate the efficacy of future disease-modification treatments in 
asymptomatic individuals. The last decade has witnessed a proliferation of studies characterizing the 
temporal sequence of the earliest functional and structural brain imaging changes in AD. These efforts have 
focused on studying individuals who are highly vulnerable to develop AD, such as those with familial genetic 
mutations, susceptibility genes (i.e. apolipoprotein epsilon-4 allele), and/or a positive family history of AD. In 
this paper, we review the rapidly growing literature of functional imaging changes in cognitively intact 
individuals who are middle-aged: positron emission tomography (PET) studies of amyloid deposition, glucose 
metabolism, as well as arterial spin labeling (ASL), task-dependent, resting-state functional magnetic 
resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS) studies.  The prevailing evidence 
points to early brain functional changes in the relative absence of cognitive impairment and structural atrophy, 
although there is marked variability in the directionality of the changes, which could, in turn, be related to 
antagonistic pleiotropy early in life. A common theme across studies relates to the spatial extent of these 
changes, most of which overlap with brain regions that are implicated in established AD. Notwithstanding 
several methodological caveats, functional imaging techniques could be preferentially sensitive to the earliest 
events of AD pathology prior to macroscopic grey matter loss and clinical manifestations of AD. We conclude 
that while these techniques have great potential to serve as biomarkers to identify at-risk individuals, more 
longitudinal studies with greater sample size and robust correction for multiple comparisons are still 
warranted to establish their utility.  
Search terms: Alzheimer's disease, neurodegeneration, preclinical dementia, functional, magnetic 
resonance imaging, positron emission tomography, neuroimaging, cognitive impairment. 
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INTRODUCTION 
There are now 46 million people living with dementia, and the number is expected to rise to 115 million in 
2050 (World Alzheimer Report 2015). Dementia is a relatively late feature in the pathophysiology of 
Alzheimer's disease (AD), with pathological changes beginning decades before symptom onset (Jack et al., 
2013). Therefore, the identification of individuals prior to the onset of significant clinical symptoms is an 
important prerequisite for the initiation of earlier treatments, particularly as they are likely to have the greatest 
potential for delaying symptom onset and slowing down cognitive decline at the earliest disease stages.  
 
Biomarkers in clinical medicine are used to predict or detect specific illnesses, monitor disease progression, 
and predict response to treatment. The search for biomarkers to detect early neurodegenerative changes 
preclinically includes the exploration of structural neuroimaging (Mak et al., 2016a), functional neuroimaging 
(Wierenga & Bondi, 2007), genomics, proteomics, neurophysiology, cerebrospinal fluid (CSF), and blood 
analysis (Van Steenoven et al., 2016). Over the past decade, a variety of imaging techniques which probe 
brain function have been used to investigate early pathological changes in individuals at risk of developing 
AD. Research participants included those with a family history of AD, carriers of apolipoprotein epsilon-4 
allele (ApoE4) and autosomal-dominant or familial AD (FAD) mutations in the genes of presenilin 1 (PSEN1), 
PSEN2 and amyloid precursor protein (APP).  Given the close relationships between the presence of these 
risk factors and AD, studying these individuals provide an invaluable opportunity to chart the natural trajectory 
of disease progression in AD (Ritchie & Ritchie, 2012). 
 
As a two-part systematic review, we have recently surveyed the structural imaging changes in preclinical 
dementia (Mak et al., 2016a). As change in brain morphology is often a late event in the neurodegenerative 
cascade, changes detectable with functional imaging may precede grey matter atrophy and white matter 
degeneration. The term functional MRI (fMRI) has become associated specifically with blood oxygen level 
dependent BOLD imaging; for the purposes of this review, however, we will consider a broader definition of 
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functional imaging to include techniques which yield information on physiology and specific pathological 
processes as well as function. We will review the literature concerning functional imaging studies in middle-
aged asymptomatic subjects under the age of 60 to survey subtle changes that arise years and even decades 
prior to the manifestations of cognitive decline. Findings will be drawn from (a) positron emission tomography 
(PET) studies of amyloid burden (11C-PIB or 18F compounds), cerebral glucose metabolism (b) perfusion MRI 
and task-based and resting-state functional magnetic resonance (fMRI) and (c) magnetic resonance 
spectroscopy (1H MRS). These techniques could have prognostic utility for identifying those at risk, predicting 
and monitoring disease progression and potentially the evaluation of a broad range of therapeutic 
interventions encompassing life-style changes, dietary improvements, and disease modifying therapies. 
 
METHOD 
The literature search used to obtain articles for the purpose of this review was done by searching Medline 
and PubMed, using key words, “preclinical” and “dementia” and “functional” and “neuroimaging” and 
“Florebetapir”, “Flumetamol”, “Florbetapen”, “Magnetic Resonance Spectroscopy”, “functional MRI”, “FDG-
PET” and “PIB”. Other terms included “brain”, “imaging”, “resting-state”, “healthy”, “young” and “middle-
aged”. Articles included were from the year 1990 till April 2016. We only considered human studies in English 
language. Articles had to describe the association between a known risk factor for dementia and 
neuroimaging changes or had to follow up a cohort originating in midlife or earlier with imaging undertaken 
at a later stage. Only studies involving functional neuroimaging modalities (PET and MRI) were included in 
this review. Relevant citations from the reference lists of identified articles were also reviewed.  
 
POSITRON EMISSION TOMOGRAPHY 
Amyloid deposition 
The advent of PET amyloid ligands has enabled the in vivo investigation of fibrillar amyloid deposition, 
heralding a rapidly growing literature in both AD and its preclinical stages (see Rabinovici & Jagust, 2009 for 
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a review). The first ligand with high specificity for amyloid was the 11C-Pittsburgh Compound B (11C-PIB) 
(Klunk et al., 2004). Subsequently, three other 18F based amyloid ligands have been developed and licensed 
for clinical use (18F-florbetapir, 18F-florbetaben and 18F-flutemetamol) (O’Brien & Herholz, 2015). Several 
studies have reported strong agreement in uptake measures among the different PET amyloid ligands 
(Villemagne et al., 2012). 
 
In AD, the topography of amyloid follows a diffuse pattern with the prefrontal cortices, precuneus and 
posterior cingulate cortex being the earliest sites of vulnerability (Rabinovici & Jagust, 2009; Thal et al., 
2002). In preclinical dementia, there is some evidence to suggest a distinct topographical pattern of amyloid 
(Figure 1A). In the first in vivo investigation of amyloid deposition in asymptomatic PSEN1 mutation carriers 
(~10 years before expected onset of cognitive symptoms), Klunk and colleagues reported preferential PIB 
binding to the striatal regions (Klunk et al., 2007). The in vivo findings were corroborated by histological 
evidence showing that the density of plaques in the striatum exceeded that of the cortex and subsequently 
confirmed by another study involving 7 PSEN1 mutation carriers and 1 APP mutation carrier (Villemagne et 
al., 2009). These in vivo findings have prompted the hypothesis that the striatum is one of the earliest sites 
of amyloid deposition (Klunk et al., 2007), thereby challenging the notion that striatal plaques only occur at 
later histopathological stages (i.e. second phase of amyloid deposition) in AD (Braak & Braak, 1990; Thal et 
al., 2002). Others have reported increased amyloid burden in the adjacent thalamus and the cerebellum in 
asymptomatic FAD mutation carriers (Knight et al., 2011; Villemagne et al., 2009). However, doubts remain 
over the universality of striatal amyloid across in FAD (Fleisher et al., 2012; Knight et al., 2011). The clinical 
relevance of PIB retention in FAD is still ambiguous. In Villemagne et al (2009), the patterns of PIB retention 
in both striatal and neocortical regions were not associated with disease severity or cognitive function. 
Neither were there significant differences in amyloid burden between dichotomized subgroups of Mini Mental 
State Examination (MMSE) scores (> 20 or <= 20) and Clinical Dementia Rating (CDR) (>2 or <= 2). 
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More recent studies from the Dominantly Inherited Alzheimer's Network study (DIAN) – a large-scale 
investigation of MRI and PET data in FAD mutation carriers – have implicated the precuneus as an early site 
of amyloid burden, approximately up to 15 years before expected symptom onset (Bateman et al., 2012). 
These findings are in accordance with those from the Colombian Alzheimer’s Prevention Initiative Registry 
(API), which includes more than 1500 living members from the largest known autosomal-dominant AD 
kindred, 30% of whom are carriers of the PSEN1 E280A mutation (Lopera et al., 1997). A unique trait of the 
Columbian kindred is that it represents the most genetically and ethnically homogenous sample from the 
same geographical location. Fleisher and colleagues (2012) characterized the pattern of fibrillar amyloid 
deposition and estimated its temporal relation with clinical onset among 30 PSEN1 mutation carriers (20 – 
56 years of age) and 20 asymptomatic non-carriers. Using a voxel-wise approach, asymptomatic mutation 
carriers (n=19) demonstrated increased 18F florbetapir binding in widespread regions encompassing the 
precuneus, cingulate regions, temporoparietal regions, frontal grey matter and the basal ganglia (Fleisher et 
al., 2012). Notably, these findings remained significant after controlling for atrophy and partial volume 
adjustments. Consistent with data from the DIAN study (Bateman et al., 2012), the trajectory of amyloid 
deposition was estimated to follow a steep acceleration (16 and 21 years before mild cognitive impairment 
(MCI) and AD respectively) before slowing to a plateau before the estimated age of onset. 
 
The Australian Imaging Biomarkers and Lifestyle (AIBL) study reported that 49% of ApoE4 carriers were 
found to be 11C-PIB positive in contrast to 21% among non-carriers (Rowe et al., 2010). In cognitively normal 
older subjects, the presence of ApoE4 has been associated with both increased and earlier amyloid 
deposition (Fleisher et al., 2013; Morris et al., 2010) as well as 3-fold increased odds of amyloid positivity 
(Mielke et al., 2012). Data from the Adult Children Study (ACS) cohort involving middle-older age individuals 
(stratified by family history for AD) have shown an age-related increase in mean cortical binding potential of 
PIB-PET that was associated with ApoE4 but not family history. Furthermore, the younger group (age < 55) 
did not show any significant associations between mean cortical binding potential (MCBP) with other CSF 
biomarkers and brain volumes (Xiong et al., 2011).  
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Cerebral glucose metabolism  
The 18F 2-fluorodeoxy-D-glucose (FDG) PET tracer has been used to quantify aberrant cerebral metabolic 
rate of glucose in AD (Minoshima et al., 1997, 1995; see Schubert, 2005 for a review) In general, preclinical 
AD appears to be characterized by a hypometabolic profile in temporo-parietal cortices including the 
precuneus. In a study of 235 volunteers aged 50 – 65 years old with a positive family history of AD, 11 ApoE4 
homozygotes were compared against 22 non-ApoE4 carriers. Despite being cognitively intact, the ApoE4 
carriers had significantly decreased glucose metabolism in regions that are often affected in AD, including 
the posterior cingulate, temporo-parietal and prefrontal regions (Reiman et al., 1996). Of note, the posterior 
cingulate and precuneus were the most hypometabolic regions (Figure 1B), in line with AD studies where it 
is regarded as a site of confluence for various pathologies including amyloid deposition, cortical atrophy and 
hypometabolism (Buckner et al., 2005). These findings in middle-aged ApoE4 carriers were subsequently 
extended to a younger sample of ApoE4 heterozygotes well before midlife (n = 12; 20 – 39 years of age) 
(Reiman et al., 2004). Furthermore, the pathological relevance of these regional metabolic deficits was 
supported by a dose-dependent correlation between ApoE4 (none, one, or two copies) in the posterior 
cingulate cortex among middle-aged persons. The authors also demonstrated that the relationship was 
significantly stronger compared to that of hippocampal glucose metabolism or volume (Fisher’s R to Z test). 
These collective findings suggest that posterior cingulate hypometabolism appear to anticipate MTL atrophy 
and provide further evidence that functional imaging techniques might be more sensitive to subtle alterations 
in the early stages of the disease. 
 
In one of the few longitudinal studies, Reiman and colleagues investigated the progression of 
hypometabolism in 10 cognitively normal ApoE4 carriers (50 – 63 years of age) over 2 years. Compared to 
non-carriers, ApoE4 carriers showed significantly more severe metabolic deficits over time in the posterior 
cingulate, fronto-temporal cortices as well as basal forebrain and the thalamus (Reiman et al., 2001).  
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Several studies have also demonstrated focal temporo-parietal metabolic deficits in FAD mutation carriers 
(Fleisher et al., 2015; Kennedy et al., 1995). Kennedy and colleagues showed an intermediate level of 
cerebral glucose metabolism in presymptomatic individuals between controls and symptomatic FAD carriers, 
whereas decreased metabolism in the precuneus was  found in presymptomatic PSEN1 carriers from the 
Columbian kindred (Fleisher et al., 2015). However, despite the consistent literature indicating 
hypometabolism in preclinical AD, the associations or differential contributions of FDG-PET and structural 
brain atrophy remains poorly understood. To address this question, Mosconi and colleagues conducted a 
multi-modal study of FDG-PET and MRI in a sample of 7 asymptomatic PSEN1 carriers (age: 35 – 49) 
(Mosconi et al., 2006). From a methodological perspective, this is one of the few studies in the literature that 
has corrected the PET scans for partial volume effects (2 segment model of brain tissue and CSF). This is 
critical in FDG-PET studies because the extent of atrophy will artificially dilute of PET measurements, thus 
inflating the degree of hypometabolism in vulnerable regions and accentuating the group-differences 
between carriers and non-carriers. Using the ROI approach to enable direct comparisons of atrophy and 
hypometabolism, the authors reported convincing evidence of hypometabolism in the MTL in the relative 
absence of atrophy. In addition, FDG-PET measurements were less variable than the MRI-based volume 
measurements, in turn resulting in stronger discriminatory sensitivity in the preclinical AD stage. Given that 
hypometabolism is thought to reflect synaptic dysfunction, these findings indicate that FDG-PET imaging 
could be more sensitive to such alterations that typically precede macroscopic grey matter atrophy.  
 
FUNCTIONAL MAGNETIC RESONANCE IMAGING  
Arterial spin labeling  
Arterial spin labeling (ASL) is a non-invasive MRI technique for the measurement of cerebral perfusion and 
it is emerging as another promising biomarker in the early stages of AD (see Hays et al., 2016 for a review). 
While cerebral glucose metabolism has been traditionally measured using radionuclide imaging as previously 
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described (FDG-PET), its widespread utility has largely been mitigated by limited availability, radiation 
exposure and costs associated with nuclear imaging. In contrast, ASL provides a measure of cerebral blood 
flow (CBF) by using magnetically labeled arterial blood water as an endogenous tracer. Its increasing use 
has been supported by showing a high degree of agreement with FDG-PET (Musiek et al., 2012). Other 
advantages include (a) greater accessibility, (b) cheaper cost of MRI compared to PET, (c) safety benefits 
(i.e. free of exposure to ionizing radiation and intravenous contrast agent and (d) simultaneous acquisition 
within a structural MRI session (~ 6 – 10 minutes). 
 
At present, there are relatively fewer ASL studies in preclinical AD, particularly in the young to middle-age 
groups. A previous study reported that resting CBF – particularly in the MTL –  was markedly increased 
(24%) in middle-aged individuals with ApoE4 and family history of AD. Interestingly, the at-risk group showed 
the opposite effect of reduced CBF in the MTL when challenged with an associative encoding task. The 
phenomena of increased baseline CBF was interpreted by the authors to represent a global compensatory 
mechanism to sustain activity in functionally impaired regions (Fleisher et al., 2009). These findings are in 
agreement with another study of individuals stratified according to maternal or paternal family history. 
Echoing previous findings where maternal history was associated with a more severe neurodegenerative 
profile (Okonkwo et al., 2012), the authors found that individuals with a maternal history of AD showed greater 
hypoperfusion in the hippocampal and fronto-parietal regions compared to both controls as well as individuals 
with a paternal family history of AD. The significance of these group differences also persisted after voxel-
wise correction for grey matter atrophy. These findings are also consistent with a previously described FDG-
PET study (Mosconi et al., 2009), and together add to a growing body of evidence implicating maternal family 
history of AD in greater cognitive decline (Debette et al., 2009).  
 
Others have demonstrated differential impact of ApoE4 on resting CBF across the lifespan (Wierenga et al., 
2013). While older ApoE4 (age = 75) adults showed decreased CBF in widespread regions, younger ApoE4 
(age = 24) had increased perfusion particularly in the anterior cingulate cortex, which was, in turn, correlated 
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with executive function (Figure 1C). However, other studies have not found any difference between young 
ApoE4 carriers (age = 28) and non-carriers (age = 29) (Filippini et al., 2009). These inconsistencies could 
be attributed to the different methodological approaches. In contrast to the whole brain voxel-wise approach 
(Wierenga et al., 2013), an ROI-based analysis was used in Filippini et al to restrict CBF comparisons to the 
hippocampus, midbrain and cerebellum. As such, any focal or subtle ApoE4 signal at the voxel-level may 
have been masked out by the averaging of voxels across the ROIs. 
 
Task-based fMRI 
fMRI offers considerable promise as a non-invasive technique that is sensitive to early functional changes in 
asymptomatic individuals. It provides an indirect measure of neuronal activity through the inference of 
changes in blood oxygen level dependent (BOLD) fMRI signal (Logothetis, 2008). Task-based fMRI studies 
typically compare BOLD signals that are evoked during one condition (i.e. remembering a word stimuli) to 
BOLD signals associated with a baseline condition or control task.  
 
ApoE4 carriers have shown reduced hippocampal and MTL activations during task performance involving 
episodic encoding, visual naming and letter fluency (Nichols et al., 2012; Smith et al., 1999; Trivedi et al., 
2006). However, decreases in functional activation have not been universally reported in ApoE4 carriers 
(Dennis et al., 2010; Filippini et al., 2009; Quiroz et al., 2010). For instance, hippocampal hyperactivity has 
been evoked during encoding in younger ApoE4 carriers (age = 28), independent of grey matter atrophy and 
perfusion changes (Figure 1D). These findings are in parallel with those of Dennis et al (2010), where young 
ApoE4 carriers (age = 23.2) also exhibited MTL hyperactivation during encoding despite comparable memory 
performance and grey matter volumes relative to non-carriers (Dennis et al., 2010). These reports, taken 
together with previous ASL studies in younger ApoE4 carriers, add further support to the notion that the role 
of ApoE4 is not uniform across the life-span. Based on the young age of the sample and the lack of behavioral 
differences between groups, MTL hyperactivity in ApoE4 carriers could be interpreted as inefficient 
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processing associated with dysfunction in the medial temporal lobe or compensatory processing necessary 
to achieve similar cognitive output to that in non-carriers (Dennis et al., 2010). Interestingly, the interactions 
between ApoE4 allele and functional changes in young adults may also be modulated by the difficulty of the 
task in question (Chen et al., 2013). Notwithsanding the caveats of a small sample size (n = 9 in each group) 
and lenient statistical thresholding (p < 0.01 uncorrected), Chen and colleagues showed that low-load 
working memory tasks (N-Back) evoked hyperactivation in ApoE4 carriers, although this effect was 
diminished with increasing working memory load. In contrast, non-carriers continued to show increasing 
levels of functional activity during the moderate and higher working memory levels of the task. 
 
Task-based functional changes have also been investigated in FAD mutation carriers (Braskie et al., 2013; 
Mondadori et al., 2006; Quiroz et al., 2010; Ringman et al., 2011). In a previous study of an FAD family (n = 
5, estimated age of clinical manifesation = 48 years), a young PSEN1 mutation carrer (age = 20) also showed 
hyperactivation in memory-related networks during episodic learning and retrieval tasks compared to controls 
(Mondadori et al., 2006). Conversely, weaker activations were observed in the middle-aged mutation carrier, 
who has an amnestic MCI profile (age = 45). Although these findings were not corrected for atrophy, the 
authors noted that manually-segmented MTL volumes were comparable between the FAD family members 
and the controls. These findings, albeit restricted to 2 PSEN1 carriers, were later supported by a larger study 
of the Columbian kindred (n = 20 carriers, age = 33) (Quiroz et al., 2010). Despite exhibiting similar cognitive 
profiles and preserved hippocampal volumes compared to controls, the young PSEN1 carriers showed 
hippocampal hyperactivation during encoding tasks of novel associations. These findings are in agreement 
with observations of decreased parietal inhibition during a memory encoding task in the youngest group of 
PSEN1 carriers studied to date (n = 19, age = 14) (Quiroz et al., 2015). Overall, the findings of hyperactivation 
– indicative of functional dysregulation – in young at-risk individuals bear resemblance to previous reports in 
MCI and AD (Dickerson et al., 2005), and collectively fit with the model that postulates a transient phase of 
functional hyperactivation followed by a steep decrease in functional activation as neuronal populations 
gradually lose their ability to engage in compensatory mechanisms  (Dickerson et al., 2005). 
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Resting-state fMRI studies 
Resting-state fMRI (RS-fMRI) is a relatively recent technique to investigate spontaneous low-frequency 
fluctuations in BOLD signals. In rsfMRI studies, subjects are asked to rest with their eyes closed or fixated 
on a cross-hair. The spontaneous temporal correlations are thought to be manifestations of intrinsic 
functional connectivity across brain networks (RSNs) (Biswal et al .,1995), which could be interrogated with 
seed-based or data-driven independent component analyses (Beckmann, 2005). 
 
The effects of ApoE4 on brain networks have been increasingly studied in preclinical AD, revealing functional 
alterations in overlapping brain regions that are disrupted in AD (Sheline & Raichle, 2013). Of particular 
interest is the default mode network (DMN), which was first described by Raichle and colleagues using PET 
data (Gusnard & Raichle, 2001; Raichle et al., 2001). The DMN encompasses the midline, frontal, MTL and 
parietal regions as well as the posterior cingulate cortex (Buckner et al., 2005). A growing body of evidence 
has implicated the DMN across the spectrum from normal aging to MCI and AD (Buckner et al., 2005; Lustig 
et al., 2003). The relevance of the DMN in the pathophysiology of dementia is also supported by the 
observations that its constituent regions are often the sites of early and focal atrophy, reduced 
perfusion/metabolism as well as fibrillary amyloid deposition (Buckner et al., 2005; Jack et al., 2013; Klunk 
et al., 2004). Therefore, the failure to suppress the DMN during task engagement may prove to be a 
promising biomarker for earlier identification of AD pathology. 
 
Abnormal DMN connectivity has been described among ApoE4 (Fleisher et al., 2009; Goveas et al., 2013; 
Patel et al., 2013) and FAD mutations carriers (Chhatwal et al., 2013). A previous study of presymptomatic 
ApoE4 carriers also reported decreased DMN connectivity in the absence of amyloid burden (Sheline et al., 
2010) (Figure 1D). Indeed, a key strength of this study was the use of in vivo amyloid PET imaging to (a) 
identify PIB-positive or negative individuals before (b) sub-stratification into those with and without an ApoE4 
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allele, thereby allowing the authors to determine whether the functional effects of ApoE4 is independent of 
the cardinal initiating event in AD (Bloom, 2014). 
 
Consistent with earlier suggestions of an antagonistic pleiotropic effect of the ApoE4 allele (Wierenga et al., 
2013), younger ApoE4 carriers have shown hippocampal hyperconnectivity within the DMN in the absence 
of cognitive deficits, structural atrophy and hypoperfusion (age range: 20 – 35 years) (Filippini et al., 2015). 
Another study has investigated a potential gender-ApoE4 interaction, revealing decreased functional 
connectivity between the hippocampus and the DMN in female carriers (Heise et al., 2014). There is also 
emerging evidence that resting-state analyses may be more sensitive than task-based fMRI to early 
perturbations in preclinical AD, as evidenced by a larger effect size (3.35 vs 1.39) in distinguishing 
asymptomatic at-risk individuals (ApoE4 and positive family history) from controls (Fleisher et al., 2009). 
There are several advantages of resting-state fMRI: (a) independence from task performance, which could 
be influenced by multiple factors unrelated to the underlying disease (i.e. interpretation of task demands, 
motivation and cognitive fluctuations); (b) ease of standardization across multi-site studies, (c) data collection 
from patients with substantial cognitive impairment (i.e. avoidance of floor effects); (d) ability to investigate 
multiple RSNs from the same datasets as opposed to unique experimental paradigms that are catered to 
specific cognitive domains. 
 
MAGNETIC RESONANCE SPECTROSCOPY 
In vivo 1H MRS allows non-invasive biochemical quantification in defined regions of the brain, and 
characteristic metabolite changes have been  recognized  in  AD and other dementias since the early 1990’s 
(Graff-Radford et al., 2014). Multiple metabolites, each thought to reflect different cellular and molecular 
aspects of the neurodegenerative process, can be measured during a single acquisition: (a) N-
acetylaspartate (NAA) is a marker of neuronal integrity; (b) myoinositol (mI) levels are thought to 
predominantly reflect glial activation; (c) Choline containing compounds (Cho) are associated with membrane 
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turnover and inflammatory processes; and metabolite levels are frequently expressed as ratios to 
creatine/phosphocreatine (Cr) . Although a substantial literature exists in dementia and MCI, there are 
currently relatively few studies in the asymptomatic stages of AD. In the Columbian kindred described 
previously, variations of 1H MRS measurements in the posterior cingulate and precuneus have been shown 
to separate asymptomatic PSEN1 mutation carriers from non-carriers with high accuracy (Londono et al., 
2014). Another study demonstrated decreases in the posterior cingulate NAA/Cr and NAA/mI among 
presymptomatic PSEN1/APP mutation carriers (n = 7). In addition, the magnitude of these deficits were 
correlated with the proximity of expected age of onset (Godbolt et al., 2006). Despite the scarcity of 1H-MRS 
studies in FAD mutation carriers, there is convergent evidence that lower NAA/Cr in the posterior cingulate 
increases the risk of dementia in MCI (Kantarci et al., 2009). Taken together, these studies provide important 
evidence that metabolic changes, particularly within the posterior cingulate and precuneus (Figure 1E), can 
be detected in presymptomatic mutation carriers before the emergence of cognitive impairment. 
 
CAVEATS AND METHODOLOGICAL CONSIDERATIONS 
Studying younger subjects at risk of familial AD has the advantage of eliminating or reducing the effects of 
other age-related comorbidities (e.g. hypertension) that may play a confounding role in cerebral pathology 
(e.g. ischemic changes). However, there are limitations to the degrees in which the findings in FAD are both 
(a) consistent and (b) generalizable to sporadic late onset AD, which could in turn hamper efforts to detect 
treatment effects due to a suboptimal choice of biomarker. There is also a scarcity of longitudinal functional 
studies, precluding definitive conclusions about the ability of the functional imaging techniques to track 
disease progression. To date, most cross-sectional studies in FAD mutation carriers have calculated the 
“estimated age of onset” (EOY) in presymptomatic carriers, but it is essentially just a construct to determine 
biomarker changes as a function of an individual’s position along the trajectory of disease course. The validity 
of EOY is inherently limited by many factors including the assumption that the parental age of onset is an 
accurate approximation for the offspring carriers. Future prospective longitudinal studies are thus required 
to follow asymptomatic FAD carriers to the symptomatic stages to confirm the predictive validity of functional 
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changes. In anticipation of future longitudinal studies, the present FAD findings could ideally be compared 
against cohorts of cognitively-normal at-risk individuals, such as those from the Alzheimer's Disease 
Neuroimaging Initiative (ADNI), Australian Imaging Biomarkers and Lifestyle (AIBL), WRAP (7 – 10 years of 
multimodal imaging data). The PREVENT study (Ritchie & Ritchie, 2012), which is an on-going study from 
our group, is also collecting large amounts of imaging data (including MRI, DTI, MRS and fMRI) from people 
aged 40 to 59 at baseline, as well as detailed neuropsychological assessment using the COGNITIO test 
battery (Ritchie et al., 2014) designed for pre-clinical cognitive assessment as well as genetic analyses.  
 
In our review, most studies have not performed partial volume correction, opting instead to (a) include grey 
matter volume as a covariate and/or (b) establish the relative absence of grey matter atrophy.  While these 
statistical adjustments are improvements over the lack of PVC, grey matter volumes are usually collinear 
with other covariates of interest such as age. It is imperative that future functional studies account for grey 
matter atrophy which could exacerbate the spillover contamination of PET/fMRI data. Due to the poor spatial 
resolution of PET and fMRI data, the intensity of a given voxel will be an aggregate of the local uptake/activity 
within the region of interest (i.e. hippocampus) and voxels from other tissue classes (i.e. white matter or 
surrounding CSF). This issue may be more problematic in cortical analyses because the cortical ribbon has 
a thickness (generally 2 to 3 mm) that is similar to the typical voxel diameters in PET and fMRI data. Since 
the partial volume effect (PVE) is proportionate to the amount of atrophy, group differences may be artificially 
attenuated (amyloid measurements) or inflated (FDG-PET, ASL and fMRI) if atrophy is not accounted for. 
 
CONCLUSIONS 
The selective investigation of individuals with increased risks of AD presents an invaluable opportunity to 
elucidate the presence, magnitude and spatial mapping of functional imaging markers associated with the 
insidious development of dementia from the presymptomatic state. The evidence reviewed herein strongly 
suggests that changes as seen on functional imaging are early features of AD. In line with the “amyloid 
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cascade” hypothesis, PET studies have established the presence of amyloid accumulation in FAD and 
ApoE4 carriers as early as 15 years before ensuing cognitive decline. However, there are still unresolved 
questions concerning the specificity and the clinical implications of regional amyloid pathology (i.e. striatal 
regions) as there is insufficient evidence for a close relationship with cognitive impairment. Metabolite 
abnormalities detected by MRS have also been demonstrated many years before predicted onset of 
dementia in FAD. Downstream events of the neurodegenerative cascade, such as hypometabolism and 
decreased CBF, are temporally closer to cognitive decline and may serve as better markers of disease 
progression. FDG-PET and ASL studies have revealed hypo-metabolism and perfusion within characteristic 
AD regions, and that these changes may even precede structural atrophy. Other research groups have 
devised novel experimental paradigms that are designed to challenge specific cognitive domains. Although 
there is clear evidence for physiological disruptions in preclinical AD, the directionality and interpretation of 
task-evoked fMRI changes are still being contested. That could be also age-dependent nuances in the 
associations between AD risk factors and functional imaging parameters. For instance, the MTL is associated 
with an upsurge of functional activity in younger ApoE4 carriers before demonstrating hypoactivation in older 
carriers as in patients with MCI and AD. Finally, although our previous review in preclinical AD has identified 
vulnerable foci of structural degeneration (Mak et al., 2016b), the independence and antecedence of 
functional deficits relative to grey matter atrophy suggests that these techniques may well be more sensitive 
to disease-related changes in preclinical AD. With more validation efforts in larger samples and longitudinal 
studies, we anticipate that functional modalities are well-poised to serve as outcome measures in future 
clinical trials. 
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FIGURE AND TABLES 
 
Figure 1. Schematic figure of the principal imaging findings. (A) At-risk individuals exhibit an atypical pattern of amyloid accumulation within the 
striatal regions, thalamus and the cerebellum. Increased amyloid has also been reported in the precuneus and the posterior cingulate cortex, 
both of which are early sites of vulnerability in MCI and AD; (B) The MTL is frequently charcterized by hypometabolism, whereas others have 
reported stronger associations between ApoE4 and hypometabolism within the posterior cingulate and precuneus compared to MTL volumes or 
metabolism; (C) Individuals with ApoE4 and a family history of AD showed decreased perfusion in the MTL that is independent of grey matter 
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atrophy. There is also evidence to imply compensatory hyperfusion in the anterior cingulate cortex among younger ApoE4 carriers; (D) fMRI task-
based studies have consistently demonstrated hypoactivation of the MTL during episodic memory tasks in older ApoE4 subjects (down-ward 
arrow). However, younger at-risk individuals tend to show hyperactivation (upward arrow). The DMN is frequently associated with functional 
abnormalities in ApoE4 and FAD mutation carriers. The effect size of rsfMRI differences has been reportedly greater compared to task-based 
fMRI; (E) 1H-MRS studies in FAD mutation carriers have reported variations of brain metabolite levels in the posterior cingulate cortex and 
precuneus. Abbreviations: MCI = Mild cognitive impairment; AD = Alzheimer’s disease, FAD = familial Alzheimer’s disease; ApoE4 = 
apolipoprotein epsilon-4 allele; MTL = medial temporal lobe, RS-fMRI = resting-state functional magnetic resonance imaging; DMN = default 
mode network; 1H-MRS = magnetic resonance spectroscopy. 
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Authors Definition of 
preclinical 
dementia 
Sample 
characteristics 
 
(number of subjects, 
mean age  SD, 
gender and 
education level in 
years) 
Imaging methods Results Correction for 
atrophy 
Correction for 
multiple 
comparisons  
Small et al 
(1995) 
ApoE4 
 
All subjects had 
a family history 
Carriers 
n = 12 (56.4  10.3) 
G = 17% male 
E = 13.9  2.7 
 
Non-carriers 
n = 19 (55.5  12.0) 
G = 47% male 
E = 15.6  1.8 
FDG-PET  Carriers showed reduced 
parietal metabolism 
compared to non-carriers.  
 
Carriers also had more 
left-right parietal 
asymmetry.  
 
No  No 
Kennedy et 
al (1995) 
Family history FH+ 
n = 24 (44.7, 31-60) 
G = NR 
E = NR 
 
Controls 
n = 16 (50.1, 35-70) 
G = NR 
E = NR 
FDG-PET Compared to controls, the 
at-risk subjects had lower 
global and temporoparietal 
glucose metabolism. 
No No 
Reiman et 
al (1996) 
ApoE4 
 
All subjects had 
a family history 
Carriers 
n = 11 (55.4  4.3) 
G= 27% male 
FDG-PET Carriers had lower glucose 
metabolism in posterior 
cingulate and bilateral 
No Yes *In searched 
volumes. 
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E = 16.5  2.4 
 
Non-carriers 
n = 22 (56.3  4.6) 
G = 27% male 
E = 15.6  2.4 
parietal, temporal and 
prefrontal regions. 
Reiman et 
al (2004) 
ApoE4 Carriers  
n = 12 (30.7  5.4) 
G = 25% male 
E = 16.0  1.7 
 
Non-carriers  
n = 15 (31.2  5.0) 
G = 20% male 
E = 16.1  1.5 
FDG-PET Carriers showed 
significantly lower glucose 
metabolism bilaterally in 
posterior cingulate, 
parietal, temporal and 
prefrontal regions. 
No difference in 
metabolic 
differences with or 
without partial 
volume correction  
 
 
Uncorrected at p < 
0.001 followed by 
Monte carlo 
correction of 
maximum 
significance levels 
in predefined ROIs 
Reiman et 
al (2005) 
ApoE4 
 
All subjects had 
family history 
ApoE4 homozygotes 
n = 36 (55.6  5.2) 
G = 36% male 
E = 15.8  2.5 
ApoE4 
heterozygotes 
n = 46 (56.1  4.2) 
G = 35% male 
E = 16.0  2.6 
 
Non-carriers 
n = 78 (56.5  4.7) 
G = 37% male 
E = 15.8  2.3 
FDG-PET ApoE4 gene dose was 
correlated with FDG-PET 
in posterior cingulate, 
precuneus, bilateral 
parietotemporal and left 
frontal cortex 
Yes Small-volume 
correction  
Mosconi et 
al (2006) 
FAD (PSEN1) Carriers  
n = 7 (42.7 ± 4.4) 
FDG-PET  Carriers showed 
widespread glucose 
Yes (2 segment 
model) 
No  
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G = 42.8% male 
E = 15.1 ± 1.0 
 
Non-carriers  
n = 7 (43.0 ± 5.0) 
G = 42.8% male  
E = 15.0 ± 1.0 
metabolism reductions in 
AD signature regions.  
 
Glucose metabolism is a 
better measure to 
differentiate carriers from 
non-carriers compared to 
structural atrophy.  
Klunk et al 
(2007) 
PSEN1  Symptomatic 
carriers  
n = 5 (35–49) 
 
Asymptomatic 
carriers 
n= 7 
Non-carriers  
n = 18 
PIB PET  Carriers have increased 
PIB retention in the 
striatum. 
 
 
No Bonferroni 
correction 
Villemagne 
et al (2009) 
FAD (PSEN1, 
PSEN2, APP) 
Carriers 
n = 8 (45.9 ± 10.5) 
G = 50% male 
E = NR 
 
AD 
n = 30 (73.6 ± 9.4) 
G = 53% male 
E = NR 
 
Controls 
n = 30 (69.8 ± 6.6) 
G = 40% male 
E = NR 
FDG-PET  
PIB-PET  
 
FAD mutation carriers 
showed high PIB retention 
in the striatum.  
No No 
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Knight et al 
(2011) 
PSEN1 Asymptomatic 
carriers  
n = 5 (34.6, 31-40) 
G = 2% male  
E = NR  
 
Symptomatic 
carriers  
n = 2 (51.5, 40-63) 
G = 0% male  
E = NR  
 
Non-carriers  
n = 10 (47.7, 25-66) 
G = 30% male  
E = NR  
 
AD  
n = 10 (61.9, 51-69) 
G = 60% male  
E = NR  
PIB-PET  Increased PIB binding in 
thalamus compared to 
sporadic AD. 
No  Hochberg 
correction 
Xiong et al 
(2011) 
Family history 
ApoE4  
 
Adult Children 
Study 
FH+ 
n = 40 (< 55 years)  
G = 25.8% male 
E = 16.0  2.4 
ApoE4 = 48.4% 
 
FH- 
n = 26 (< 55 years) 
G = 37.2% male 
E = 16.1  2.7 
ApoE4 = 25.5% 
PIB-PET  
 
 
For young subjects, 
amyloid deposition 
increased by age at a 
significantly faster pace for 
individuals with ApoE4, 
compared with the pace 
for those without ApoE4, 
leading to a higher level of 
binding in ApoE4 carriers.  
No No 
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Bateman et 
al (2012) 
FAD (PSEN1, 
PSEN2, APP) 
 
Carriers 
n = 88 (39.1  10.3) 
G = 41% male 
E = 13.9  2.5 
ApoE4 = 25% 
 
Non-carriers 
n = 40 (39.5  8.9) 
G = 42% male 
E = 15.0  2.5 
ApoE4 = 22% 
PIB-PET 
FDG-PET  
 
 
Non-carriers did not show 
detectable amyloid 
deposition.  
 
 
Carriers had significant 
amyloid deposition in the 
precuneus 15 years before 
expected symptom onset. 
Cerebral hypometabolism 
was observed 10 years 
before expected symptom 
onset. 
 
 
Output volumes 
were corrected for 
total intracranial 
volume using 
established 
methods 
 
No 
Fleisher et 
al (2012) 
FAD (PSEN1) 
 
Colombian 
kindred  
 
Symptomatic 
carriers 
n = 11 (47.5  4.6) 
G = 27% male 
E = 8.8  3.5 
 
Presymptomatic 
carriers 
n = 19 (32.6  8.2) 
G = 37% male 
E = 12.3  2.8 
 
Non-carriers  
n = 20 (33.9  8.7) 
G = 35% male 
E = 11.2  3.3 
Florbetapir PET  
 
 
Asymptomatic mutation 
carriers showed greater 
amyloid deposition 
compared to age matched 
non-carriers. 
 
Lack of striatal binding. 
No No 
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Protas et al 
(2013) 
ApoE4 ApoE4/E4 
n = 31 (55.5 ± 5.1) 
G = 32% 
E = 15.7 ± 1.4 
 
ApoE4/E3 
n = 42 (55.9 ± 4.0) 
G = 35% male  
E = 15.3 ± 1.5 
 
Non-carriers 
n = 76 (56.5 ± 4.7) 
G = 36% male  
E = 15.8 ± 1.5 
FDG-PET  There were group 
differences (ApoE gene 
dose effect) for posterior 
cingulate glucose 
metabolism. 
 
Gene dose was correlated 
with posterior cingulate 
metabolism 
(r=0.3,p<0.001). This 
association was 
significantly stronger 
compared to hippocampal 
volume and metabolism. 
No p < 0.001 
uncorrected 
followed by Monte 
Carlo procedure to 
correct maximal 
significance levels 
for multiple 
comparisons in 
predefined ROI 
Arenaza- 
Urquijo et 
al (2015) 
ApoE4  Carriers  
n = 28 (52.7 ± 17.1) 
G = 50% male  
E = 13.7 ± 3.6 
 
Non-carriers  
n = 44 (53.8 ± 15.8) 
G = 66% male 
E = 12.6 ± 3.5 
FDG-PET 
Florbetapir PET  
 
Higher education is 
associated with greater 
frontotemporal metabolism 
only in carriers of ApoE4. 
 
This was independent from 
amyloid deposition. 
Yes  Uncorrected at p < 
0.005 and K > 
1000mm3 
Fleisher et 
al (2015) 
PSEN1 Cognitively 
unimpaired carriers 
n = 20 (32.0 ± 9.0) 
G = 33% male  
E = 12.0 ± 3.0 
 
Cognitively impaired 
carriers 
n = 12 (49.0 ± 5.0) 
FDG-PET: ROI 
and voxelwise 
Florbetapir PET  
PSEN carriers showed 
lower cerebral glucose 
metabolism in the 
precuneus. 
No  Uncorrected at p < 
0.005 
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G = 40% male 
E = 8.0 ± 4.0 
 
Non-carriers  
n = 22 (33.0 ± 9.0) 
G = 41% male 
E = 11.0 ± 3.0 
 
Table 1. Summary of PET studies. Notes. AD: Alzheimer’s disease; ApoE: apolipoprotein; DMN: default mode network; E: education; FAD: 
familial Alzheimer’s disease; FDG: fludeoxyglucose; FH: family history; G: gender; HC; healthy controls; MCI: mild cognitive impairment; NR: 
not reported; PET: positron emission tomography; PIB: Pittsburgh compound B; PSEN: presenilin; ROI: region of interest; SUVR: standardized 
uptake value ratio.
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Authors Definition of 
preclinical 
dementia 
Sample 
characteristics 
 
(number of 
subjects, mean 
age  SD, gender 
and education 
level in years) 
Imaging 
methods  
and tasks  
Results Correction for 
atrophy 
Correction for 
multiple 
comparisons 
Smith et al (1999) ApoE4  
 
Family history  
ApoE4 FH+ 
n = 14 (51.8  5.1) 
G = 0% male 
E = 14.8  2.7 
 
Non-carriers, FH- 
n = 12 (53.0  6.2) 
G = 0% male 
E = 14.7  2.1 
fMRI  
 
Visual naming 
Letter fluency 
ApoE4 FH+ subjects had 
lower activation in the 
bilateral mid and posterior 
inferotemporal regions 
during both visual naming 
and letter fluency tasks. 
No  No  
Chen et al (2013) ApoE4  
 
Carriers 
n = 9 (42.1  9.1) 
G = 44% male 
E = NR 
 
Non-carriers 
n = 9 (42.8  9.6) 
G = 44% male 
E = NR 
fMRI  
 
3 difficulty levels 
of the N-back 
task 
At low levels of task load, 
the carriers showed 
increased functional 
activation than the non-
carriers.  
 
The increase in activation 
was attenuated at higher 
levels of working memory 
load. 
No  No  
 
Lenient threshold 
of p < 0.01 
uncorrected and 
a minimum 
cluster extent of 
3 contiguous 
voxels 
Mondadori et al 
(2006) 
PSEN1 Young PSEN1 
n = 3 (21.0  1.4) 
G = NR 
E = 13.3  1.3 
 
fMRI  
 
Episodic 
learning, 
retrieval, and 
Young PSEN1 subjects 
showed enhanced activity 
in left frontal, temporal, 
and parietal neocortices 
during learning, retrieval, 
No No 
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Middle aged 
PSEN1 
n = 2 (48.5  3.5) 
G = NR 
E = 11.0  2.0 
 
Controls 
n = 21 (22.2  1.8) 
G = NR 
E = 14.1  1.4 
working 
memory task 
and novelty detection 
compared to controls 
despite having the equal 
performance. 
 
The middle-aged group 
had very low brain activity 
increases during learning 
and retrieval tasks.  
 
Trivedi et al (2006)  ApoE4 
Family history 
Carriers  
n = 23 (54.0  5.6) 
G = 43% male  
E = 16.5  2.6 
 
Non-carriers  
n = 17 (52.1  6.8) 
G = 35% male  
E = 15.9  2.1 
fMRI  
 
Episodic 
encoding task  
Carriers showed lower 
hippocampal and MTL 
activation compared to 
non-carriers. 
No FDR correction 
for whole brain 
group 
comparisons 
 
 
  
Fleisher et al (2009) ApoE4 
 
Family history 
 
High Risk 
n = 17 (58.6  4.1) 
G = 23.5% male 
E= 16.0  2.0 
 
Low Risk 
n = 12 (57.6  4.5) 
G = 41.7% male 
E = 16.0  2.4 
RS-fMRI 
 
fMRI  
Associative 
encoding task  
The high risk group 
showed increased 
connectivity in the 
prefrontal cortex, left 
postcentral gyrus, 
temporal gyrus, and the 
right hippocampus. 
Decreased connectivity 
was found in the 
precuneus and the gyrus 
rectus. 
 
No  AlphaSim 
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Fleisher et al (2009) ApoE4 
Family history 
High Risk 
n = 13 (58.2 ~ 4.3) 
G = 78% female 
E = 15.9 
 
Low risk 
n = 10 (57.7 ~ 4.4) 
G = 50% female 
E = 16.3 
ASL 
 
Increased resting 
perfusion in the MTL 
No Monte Carlo 
simulation 
Filippini et al (2009) ApoE4 ApoE4 carriers 
n = 18 (28.4  4.9) 
G = 61% male 
E = 19.6  2.0 
 
Non-carriers 
n = 18 (28.6  3.9) 
G = 55.6% male 
E = 19.5  1.5 
fMRI  
 
Encoding 
memory task  
The encoding task 
produced greater 
hippocampal activation in 
ApoE4 carriers relative to 
non-carriers.  
 
ApoE4 carriers showed 
increased hippocampal 
activation in the DMN 
compared to non-carriers.
Grey matter 
maps and resting 
CBF maps were 
included as 
nuisance 
covariates.  
Cluster-wise 
correction 
Dennis et al (2010) ApoE4 Carriers 
n = 12 (23.2  3.3) 
G = 42% male 
E = NR 
 
Non-carriers 
n = 12 (22.8  2.6) 
G = 25% male 
E = NR 
fMRI  
 
Encoding 
memory task 
Carriers showed more 
task-related activity in the 
medial temporal lobe 
compared to non-carriers. 
 
Carriers also had more 
connectivity between the 
medial temporal lobe and 
posterior cingulate, 
however overall 
connectivity was reduced 
across the anterior and 
posterior cortices. 
No  No 
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Quiroz et al (2010) PSEN1 
 
Colombian 
kindred 
 
Carriers  
n = 20 (33.7  6.0) 
G = 30% male 
E = 10.7  2.4 
 
Non-carriers 
n = 19 (34.5  6.5) 
G = 16% male 
E =10.8  3.3 
fMRI  
Face-name 
associative 
encoding task  
 
Carriers showed 
increased activity in the 
right hippocampus during 
the encoding task 
compared to non-carriers. 
 
Both groups had equal 
performance on the task.  
Adjusted for 
hippocampal 
volumes 
Whole brain 
exploratory 
analyses: p < 
0.005 (extent 
threshold = 20 
voxels) 
uncorrected 
 
Partial 
correlations were 
corrected for 
multiple 
comparisons 
using Bonferroni  
Sheline et al (2010) ApoE4 
 
Carriers 
n = 38 (58.8  8.5) 
G = 23.7% male 
E = 16.2  2.0 
 
Non-carriers 
n = 62 (63.3  7.4) 
G = 30.6% male 
E = 16.0  2.6 
RS-fMRI Compared to non-
carriers, carriers showed 
increased functional 
connectivity in frontal 
regions whereas 
decreased connectivity 
was found in 
hippocampus, 
parahippocampus and 
middle temporal cortex. 
No  Bonferroni 
correction 
Ringman et al (2011)  FAD  
ApoE 
FAD Carriers  
n = 14 (29.9, 23-
43) 
G = 14.3% male  
E = NR  
 
fMRI  
Novelty 
encoding task 
FAD carriers had lower 
BOLD signal in the 
anterior cingulate gyrus 
relative to FAD non-
carriers.  
 
No  Cluster-wise 
correction   
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FAD non-carriers 
n = 9 (37.3, 19-55) 
G = 22.2% male  
E = NR  
 
ApoE3/E4 
n = 4 (40.0, 29-55) 
G = 25% male  
E = NR  
 
ApoE3/E3 
n = 14 (30.4, 19-
46) 
G = 21% male  
E = NR  
 
ApoE3/E2 
n = 5 (33.8, 26-43) 
G = 0% male  
E = NR  
ApoE4 carriers showed 
higher BOLD activation in 
the occipital and 
perisylvian cortices 
compared to ApoE4 non-
carriers. 
Nichols et al (2012) ApoE ApoE2/E3 
n = 11 (27.0  3.4) 
G = 18% male 
E = 17.0  1.4 
 
ApoE3/E3 
n = 57 (27.0  5.3) 
G = 42% male 
E = 17.0  2.4 
 
ApoE3/E4 
fMRI  
 
Encoding and 
retrieval tasks 
ApoE4 carriers 
demonstrated less 
activation in the 
hippocampi compared to 
ApoE3 carriers during 
encoding and retrieval.  
 
 
No  Family-wise error 
rate correction 
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n = 23 (38.0  
16.7) 
G = 39% 
E = 17.0  1.5 
Trachtenberg et al 
(2012) 
ApoE 
 
ApoE2/E3 
n = 23 (44.7  4.3) 
G = 52.2% male 
E = 14.4  2.2 
 
ApoE3/E3 
n = 20 (47.0  1.6) 
G = 50% male 
E = 15.0  2.6 
 
ApoE3/E4 
n = 26 (46.0  5.7) 
G = 53.8% male 
E = 14.0  2.6 
 
ApoE4/ E4 
n = 8 (46.1  6.9) 
G = 37.5% male 
E = 14.1  4.5 
RS-fMRI No effect of ApoE 
genotype on functional 
connectivity in the DMN. 
Gray matter 
maps as voxel-
wise covariates 
Family-wise error 
rate correction 
Goveas et al (2013) ApoE4 
 
Carriers 
n = 20 (52.4  5.6) 
G = 30% male 
E = 15.0  2.4 
 
Non-carriers 
n = 26 (54.5  5.8) 
G = 34.6% male 
RS-fMRI Carriers had reduced 
functional connectivity in 
DMN and executive 
control network, except 
for increased connection 
in the salience network 
compared to non-carriers. 
 
No  AlphaSim 
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E = 15.6  2.5 There were no 
differences in gray matter 
volumes and cognitive 
performance.  
Chhatwal et al (2013) FAD (PSEN1, 
PSEN2, APP) 
 
 
Carriers 
n = 44 (34.6  8.0) 
G = 38.6% male 
E = NR 
 
Non-carriers 
n = 37 (38.9  9.7) 
G = 45.9% male 
E = NR
RS-fMRI Carriers showed 
decreased functional 
connectivity in the 
precuneus, posterior 
cingulate and right 
parietal cortex compared 
to non-carriers. 
No  No 
Braskie et al (2013) FAD  Carriers  
n = 9 (29.8  5.6) 
G = 11 % male  
E = 12.9  3.1 
 
Non-carriers  
n = 8 (35.0  8.5) 
G = 12.5 % male  
E = 12.5  4.5 
fMRI 
 
Verbal paired 
associates task 
to measure 
memory 
performance 
Carriers showed 
decreased hippocampal  
and temporo-parietal 
activation. 
Total normalised 
gray matter 
volume and 
bilateral 
hippocampal 
volumes included 
as nuisance 
covariates.  
Yes  
Patel et al (2013) ApoE4 Carriers  
n = 14 (43.0 ± 7.8) 
G = 43% male  
E = NR  
 
Non-carriers  
n = 22 (45.0 ± 8.3) 
G = 41% male 
E = NR 
RS-fMRI Carriers showed reduced 
DMN functional 
connectivity. 
No  Family-wise error 
rate correction 
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Wierenga et al (2013) ApoE Young carriers  
n = 15 (23.6 ± 3.1) 
G = 20% male 
E = 14.9 ± 0.3 
 
Young non-carriers 
n = 15 (23.3 ± 3.0) 
G = 47% male  
E = 15.0 ± 0.5 
 
Old carriers  
n = 16 (75.1 ± 7.9) 
G = 31% male  
E = 16.6 ± 1.6 
 
Old non-carriers  
n = 24 (72.4 ± 6.0) 
G = 33% male  
E = 16.1 ± 2.0 
ASL 
 
Carriers showed more 
CBF in the left lingual 
gyrus and precuneus 
compared to non-carrier, 
particularly in the young 
carrier group. 
 
Significant interaction 
effect between age and 
ApoE in the left anterior 
cingulate cortex: young 
carriers showed 
increased blood flow. 
Yes  Yes 
Heise et al (2014) ApoE4 Male ApoE4  
n = 20 (49.2 ± 8.7) 
E = 14.4 ± 3.4 
 
Female ApoE4  
n = 26 (54.2 ± 
12.8) 
E = 14.8 ± 3.5 
 
Male ApoE3/E3  
n = 18 (54.4 ± 
10.4) 
E = 15.7 ± 3.4 
RS-fMRI Female carriers had 
lower functional 
connectivity between the 
hippocampus and 
precuneus/posterior 
cingulate cortex. 
GM images 
added to the 
GLM as 
covariates 
Familywise-error-
rate correction 
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Female ApoE3/E3 
n = 22 (57.8 ± 
10.1) 
E = 16.1 ± 3.2 
Okonkwo et al (2012) Family history  Asymptomatic 
group 
n = 252 (59.2 ± 
6.5) 
G = 31.8% male  
E = 16.4 ± 2.7 
FH = 70.2% 
ApoE4 = 54.2% 
ASL Maternal FH was 
associated with 
hippocampal and 
parietofrontal 
hypoperfusion compared 
to controls and paternal 
FH.  
 
Main findings 
persisted after 
correcting for 
atrophy.  
Monte-Carlo 
simulations for 
voxel-wise tests 
Yang et al (2013) ApoE4 Young carriers  
n = 16 (28.8 ± 5.6) 
G = 37.5% male  
E = 16.9 ± 2.3 
 
Young non-carriers 
n = 84 (26.9 ± 4.0) 
G = 56% male  
E = 17.8 ± 2.6 
 
Old Carriers 
n = 17 (69.4 ± 7.4) 
G = 47.1 % male 
E = 11.5 ± 6.5 
 
Old non-carriers  
n = 95 (68.2 ± 6.4) 
G = 48.4% male  
E = 11.4 ± 5.5 
RS-fMRI 
 
 
There was no effect of 
ApoE4 on BOLD 
complexity in the young 
group. 
No  Familywise-error-
rate correction  
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Quiroz et al (2015) PSEN1 
 
Colombian 
kindred  
Non-carriers  
n = 19 (13 ± 3) 
G = 47% male  
E = 7.0 ± 3.0 
 
Carriers  
n = 18 (13 ± 2) 
G = 33% male  
E = 7.0 ± 3.0 
fMRI and RS-
fMRI 
 
Associative 
memory 
encoding 
Carriers showed less 
memory encoding task-
related deactivation in 
parietal regions 
compared to non-carriers. 
Carriers also had more 
functional connectivity of 
the posterior cingulate 
cortex with MTL regions. 
No  Yes 
Su et al (2015) ApoE 
 
ApoE4  
n = 31 (24.0, 25–
22) 
G = 45% male 
E = 16.0 
 
ApoE3  
n = 31 (22.0, 25–
22) 
G = 45% male 
E = 16.0 
 
ApoE2  
n = 14 (23.5 ± 2.1) 
G = 43% male 
E = 16.0 
RS-fMRI 
ASL 
ApoE4 carriers showed 
increased functional 
connectivity in the DMN. 
 
There were no 
differences in cerebral 
blood flow between the 
groups. 
Yes  Alphasim 
correction 
Dowell et al (2016)  ApoE4 Young group 
ApoE4 
n = 21 (21.4 ± 2.2) 
G = 38% male  
E = 15.1 ± 0.2 
 
RS-fMRI Young ApoE3/E3 carriers 
showed greater functional 
connectivity.  
No  False discovery 
rate correction 
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Young group 
ApoE3/E3 
n = 20 (20.9 ± 1.4) 
G = 30% male  
E = 15.1 ± 0.3 
 
Middle aged group 
ApoE4 
n = 17 (49.4 ± 3.9) 
G = 29% male  
E = 15.0 ± 1.6 
 
Middle aged group 
ApoE3/E3  
n = 20 (50.5 ± 4.5) 
G = 45% male  
E = 14.6 ± 1.6 
 
Table 2. Summary of fMRI studies. Notes. AD: Alzheimer’s disease; ApoE: apolipoprotein; BOLD: Blood-oxygen-level dependent; DMN: default 
mode network; E: education; FAD: familial Alzheimer’s disease; FH: family history; fMRI: functional magnetic resonance; G: gender; NR: not 
reported; PSEN: presenilin. 
 
Table 3. Summary of longitudinal studies. Notes. AD: Alzheimer’s disease; ApoE: apolipoprotein; BOLD: Blood-oxygen-level dependent; E: 
education; FH: family history; fMRI: functional magnetic resonance imaging; G: gender; PET: positron emission tomography. 
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Authors Definition of 
preclinical 
 
Sample 
characteristics
(number of 
subjects, 
mean age  
SD, gender 
and education 
level in years)
  
Imaging methods Results Correction for atrophy Correction for multiple 
comparisons 
Reiman 
et al 
(2001) 
ApoE4 
 
All subjects 
had a family 
history  
 
Carriers 
n = 10 (55.9  
3.4) 
G = 30% male
E = 15.4  2.9 
 
Non-carriers 
n = 15 (57.1  
4.4) 
G = 33% male
E = 16.1  1.9 
FDG-PET Carriers showed greater 
glucose metabolism 
declines over 2 years in 
temporal, posterior 
cingulate, prefrontal 
cortex, basal forebrain, 
parahippocampal gyrus 
and thalamus compared 
to non-carriers. 
No No 
Smith et 
al (2005) 
ApoE4 
 
Family history  
 
First Test 
Session 
 
High Risk 
Group  
n = 14 (53.5  
1.7) 
fMRI 
 
Confrontation 
object naming 
task 
 
 
The high-risk group 
showed reduced 
activation in occipital and 
inferiortemporal regions 
at baseline. 
 
At follow-up, the high-risk 
No  No  
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G = 0% male 
E = 15.6  0.6 
 
Low Risk 
Group  
n = 9 (54.7  
2.1) 
G = 0% male 
E = 14.5  0.7 
 
Second Tests 
Session  
 
High Risk 
Group  
n = 14 (57.4  
1.9) 
G = 0% male 
E = 15.6  0.6 
 
Low Risk 
Group  
n = 9 (58.3  
2.2) 
G = 0% male 
E = 14.5  0.7 
group showed greater 
and more spatially 
extensive hypoactivations 
in posterior inferomedial 
temporal and occipital 
lobes compared to the 
low risk group.  
 
